Why Caesars’ Digital Arm May Be the Gaming Giant’s Best-Kept Secret
It’s not often that a company with the scale and…
Sell
24
XHS Quote, Financials, Valuation and Earnings
Last price:
$89.86
Seasonality move
:
3.31%
Day range:
$88.94 - $90.92
52-week range:
$85.93 - $100.30
Dividend yield:
0.34%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
--
Volume:
1.4K
Avg. volume:
2.5K
1-year change:
4.04%
Market cap:
--
Revenue:
--
EPS (TTM):
--
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
XHS
SPDR S&P Health Care Services ETF
|
$90.63 | -- | -- | -- | $0.09 | 0.34% | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
$24.33 | -- | -- | -- | $0.24 | 0.99% | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
$60.26 | -- | -- | -- | $0.00 | 0% | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
$26.98 | -- | -- | -- | $0.13 | 1.66% | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
$9.89 | -- | -- | -- | $0.00 | 0% | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
$67.22 | -- | -- | -- | $0.01 | 0.05% | -- |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
XHS
SPDR S&P Health Care Services ETF
|
-- | 1.413 | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | 1.890 | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | 1.316 | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | 1.073 | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | 2.318 | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | 1.301 | -- | -- |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
XHS
SPDR S&P Health Care Services ETF
|
-- | -- | -- | -- | -- | -- |
|
BBC
Virtus LifeSci Biotech Clinical Trials ETF
|
-- | -- | -- | -- | -- | -- |
|
BBP
Virtus LifeSci Biotech Products ETF
|
-- | -- | -- | -- | -- | -- |
|
FTXH
First Trust Nasdaq Pharmaceuticals ETF
|
-- | -- | -- | -- | -- | -- |
|
GNOM
Global X Genomics & Biotechnology ETF
|
-- | -- | -- | -- | -- | -- |
|
PBE
Invesco Biotechnology & Genome ETF
|
-- | -- | -- | -- | -- | -- |
SPDR S&P Health Care Services ETF vs. Competitors
-
Which has Higher Returns XHS or BBC?
Virtus LifeSci Biotech Clinical Trials ETF has a net margin of -- compared to SPDR S&P Health Care Services ETF's net margin of --. SPDR S&P Health Care Services ETF's return on equity of -- beat Virtus LifeSci Biotech Clinical Trials ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XHSSPDR S&P Health Care Services ETF-- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- -
What do Analysts Say About XHS or BBC?
SPDR S&P Health Care Services ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Clinical Trials ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Health Care Services ETF has higher upside potential than Virtus LifeSci Biotech Clinical Trials ETF, analysts believe SPDR S&P Health Care Services ETF is more attractive than Virtus LifeSci Biotech Clinical Trials ETF.
Company Buy Ratings Hold Ratings Sell Ratings XHSSPDR S&P Health Care Services ETF0 0 0 BBCVirtus LifeSci Biotech Clinical Trials ETF0 0 0 -
Is XHS or BBC More Risky?
SPDR S&P Health Care Services ETF has a beta of 1.019, which suggesting that the stock is 1.88% more volatile than S&P 500. In comparison Virtus LifeSci Biotech Clinical Trials ETF has a beta of 1.043, suggesting its more volatile than the S&P 500 by 4.293%.
-
Which is a Better Dividend Stock XHS or BBC?
SPDR S&P Health Care Services ETF has a quarterly dividend of $0.09 per share corresponding to a yield of 0.34%. Virtus LifeSci Biotech Clinical Trials ETF offers a yield of 0.99% to investors and pays a quarterly dividend of $0.24 per share. SPDR S&P Health Care Services ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Clinical Trials ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XHS or BBC?
SPDR S&P Health Care Services ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Clinical Trials ETF quarterly revenues of --. SPDR S&P Health Care Services ETF's net income of -- is lower than Virtus LifeSci Biotech Clinical Trials ETF's net income of --. Notably, SPDR S&P Health Care Services ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Clinical Trials ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Health Care Services ETF is -- versus -- for Virtus LifeSci Biotech Clinical Trials ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XHSSPDR S&P Health Care Services ETF-- -- -- -- BBCVirtus LifeSci Biotech Clinical Trials ETF-- -- -- --
-
Which has Higher Returns XHS or BBP?
Virtus LifeSci Biotech Products ETF has a net margin of -- compared to SPDR S&P Health Care Services ETF's net margin of --. SPDR S&P Health Care Services ETF's return on equity of -- beat Virtus LifeSci Biotech Products ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XHSSPDR S&P Health Care Services ETF-- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- -
What do Analysts Say About XHS or BBP?
SPDR S&P Health Care Services ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Virtus LifeSci Biotech Products ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Health Care Services ETF has higher upside potential than Virtus LifeSci Biotech Products ETF, analysts believe SPDR S&P Health Care Services ETF is more attractive than Virtus LifeSci Biotech Products ETF.
Company Buy Ratings Hold Ratings Sell Ratings XHSSPDR S&P Health Care Services ETF0 0 0 BBPVirtus LifeSci Biotech Products ETF0 0 0 -
Is XHS or BBP More Risky?
SPDR S&P Health Care Services ETF has a beta of 1.019, which suggesting that the stock is 1.88% more volatile than S&P 500. In comparison Virtus LifeSci Biotech Products ETF has a beta of 0.627, suggesting its less volatile than the S&P 500 by 37.32%.
-
Which is a Better Dividend Stock XHS or BBP?
SPDR S&P Health Care Services ETF has a quarterly dividend of $0.09 per share corresponding to a yield of 0.34%. Virtus LifeSci Biotech Products ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SPDR S&P Health Care Services ETF pays -- of its earnings as a dividend. Virtus LifeSci Biotech Products ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XHS or BBP?
SPDR S&P Health Care Services ETF quarterly revenues are --, which are smaller than Virtus LifeSci Biotech Products ETF quarterly revenues of --. SPDR S&P Health Care Services ETF's net income of -- is lower than Virtus LifeSci Biotech Products ETF's net income of --. Notably, SPDR S&P Health Care Services ETF's price-to-earnings ratio is -- while Virtus LifeSci Biotech Products ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Health Care Services ETF is -- versus -- for Virtus LifeSci Biotech Products ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XHSSPDR S&P Health Care Services ETF-- -- -- -- BBPVirtus LifeSci Biotech Products ETF-- -- -- --
-
Which has Higher Returns XHS or FTXH?
First Trust Nasdaq Pharmaceuticals ETF has a net margin of -- compared to SPDR S&P Health Care Services ETF's net margin of --. SPDR S&P Health Care Services ETF's return on equity of -- beat First Trust Nasdaq Pharmaceuticals ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XHSSPDR S&P Health Care Services ETF-- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- -
What do Analysts Say About XHS or FTXH?
SPDR S&P Health Care Services ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand First Trust Nasdaq Pharmaceuticals ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Health Care Services ETF has higher upside potential than First Trust Nasdaq Pharmaceuticals ETF, analysts believe SPDR S&P Health Care Services ETF is more attractive than First Trust Nasdaq Pharmaceuticals ETF.
Company Buy Ratings Hold Ratings Sell Ratings XHSSPDR S&P Health Care Services ETF0 0 0 FTXHFirst Trust Nasdaq Pharmaceuticals ETF0 0 0 -
Is XHS or FTXH More Risky?
SPDR S&P Health Care Services ETF has a beta of 1.019, which suggesting that the stock is 1.88% more volatile than S&P 500. In comparison First Trust Nasdaq Pharmaceuticals ETF has a beta of 0.658, suggesting its less volatile than the S&P 500 by 34.157%.
-
Which is a Better Dividend Stock XHS or FTXH?
SPDR S&P Health Care Services ETF has a quarterly dividend of $0.09 per share corresponding to a yield of 0.34%. First Trust Nasdaq Pharmaceuticals ETF offers a yield of 1.66% to investors and pays a quarterly dividend of $0.13 per share. SPDR S&P Health Care Services ETF pays -- of its earnings as a dividend. First Trust Nasdaq Pharmaceuticals ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XHS or FTXH?
SPDR S&P Health Care Services ETF quarterly revenues are --, which are smaller than First Trust Nasdaq Pharmaceuticals ETF quarterly revenues of --. SPDR S&P Health Care Services ETF's net income of -- is lower than First Trust Nasdaq Pharmaceuticals ETF's net income of --. Notably, SPDR S&P Health Care Services ETF's price-to-earnings ratio is -- while First Trust Nasdaq Pharmaceuticals ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Health Care Services ETF is -- versus -- for First Trust Nasdaq Pharmaceuticals ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XHSSPDR S&P Health Care Services ETF-- -- -- -- FTXHFirst Trust Nasdaq Pharmaceuticals ETF-- -- -- --
-
Which has Higher Returns XHS or GNOM?
Global X Genomics & Biotechnology ETF has a net margin of -- compared to SPDR S&P Health Care Services ETF's net margin of --. SPDR S&P Health Care Services ETF's return on equity of -- beat Global X Genomics & Biotechnology ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XHSSPDR S&P Health Care Services ETF-- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- -
What do Analysts Say About XHS or GNOM?
SPDR S&P Health Care Services ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Global X Genomics & Biotechnology ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Health Care Services ETF has higher upside potential than Global X Genomics & Biotechnology ETF, analysts believe SPDR S&P Health Care Services ETF is more attractive than Global X Genomics & Biotechnology ETF.
Company Buy Ratings Hold Ratings Sell Ratings XHSSPDR S&P Health Care Services ETF0 0 0 GNOMGlobal X Genomics & Biotechnology ETF0 0 0 -
Is XHS or GNOM More Risky?
SPDR S&P Health Care Services ETF has a beta of 1.019, which suggesting that the stock is 1.88% more volatile than S&P 500. In comparison Global X Genomics & Biotechnology ETF has a beta of 1.125, suggesting its more volatile than the S&P 500 by 12.532%.
-
Which is a Better Dividend Stock XHS or GNOM?
SPDR S&P Health Care Services ETF has a quarterly dividend of $0.09 per share corresponding to a yield of 0.34%. Global X Genomics & Biotechnology ETF offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. SPDR S&P Health Care Services ETF pays -- of its earnings as a dividend. Global X Genomics & Biotechnology ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XHS or GNOM?
SPDR S&P Health Care Services ETF quarterly revenues are --, which are smaller than Global X Genomics & Biotechnology ETF quarterly revenues of --. SPDR S&P Health Care Services ETF's net income of -- is lower than Global X Genomics & Biotechnology ETF's net income of --. Notably, SPDR S&P Health Care Services ETF's price-to-earnings ratio is -- while Global X Genomics & Biotechnology ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Health Care Services ETF is -- versus -- for Global X Genomics & Biotechnology ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XHSSPDR S&P Health Care Services ETF-- -- -- -- GNOMGlobal X Genomics & Biotechnology ETF-- -- -- --
-
Which has Higher Returns XHS or PBE?
Invesco Biotechnology & Genome ETF has a net margin of -- compared to SPDR S&P Health Care Services ETF's net margin of --. SPDR S&P Health Care Services ETF's return on equity of -- beat Invesco Biotechnology & Genome ETF's return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital XHSSPDR S&P Health Care Services ETF-- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- -
What do Analysts Say About XHS or PBE?
SPDR S&P Health Care Services ETF has a consensus price target of --, signalling downside risk potential of --. On the other hand Invesco Biotechnology & Genome ETF has an analysts' consensus of -- which suggests that it could fall by --. Given that SPDR S&P Health Care Services ETF has higher upside potential than Invesco Biotechnology & Genome ETF, analysts believe SPDR S&P Health Care Services ETF is more attractive than Invesco Biotechnology & Genome ETF.
Company Buy Ratings Hold Ratings Sell Ratings XHSSPDR S&P Health Care Services ETF0 0 0 PBEInvesco Biotechnology & Genome ETF0 0 0 -
Is XHS or PBE More Risky?
SPDR S&P Health Care Services ETF has a beta of 1.019, which suggesting that the stock is 1.88% more volatile than S&P 500. In comparison Invesco Biotechnology & Genome ETF has a beta of 0.819, suggesting its less volatile than the S&P 500 by 18.07%.
-
Which is a Better Dividend Stock XHS or PBE?
SPDR S&P Health Care Services ETF has a quarterly dividend of $0.09 per share corresponding to a yield of 0.34%. Invesco Biotechnology & Genome ETF offers a yield of 0.05% to investors and pays a quarterly dividend of $0.01 per share. SPDR S&P Health Care Services ETF pays -- of its earnings as a dividend. Invesco Biotechnology & Genome ETF pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios XHS or PBE?
SPDR S&P Health Care Services ETF quarterly revenues are --, which are smaller than Invesco Biotechnology & Genome ETF quarterly revenues of --. SPDR S&P Health Care Services ETF's net income of -- is lower than Invesco Biotechnology & Genome ETF's net income of --. Notably, SPDR S&P Health Care Services ETF's price-to-earnings ratio is -- while Invesco Biotechnology & Genome ETF's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for SPDR S&P Health Care Services ETF is -- versus -- for Invesco Biotechnology & Genome ETF. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income XHSSPDR S&P Health Care Services ETF-- -- -- -- PBEInvesco Biotechnology & Genome ETF-- -- -- --
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will Tyson Foods Stock Bounce Back?
Tyson Foods, Inc. (NYSE:TSN) is one of the biggest food…
Will Iovance Biotherapeutics Stock Bounce Back?
Iovance Biotherapeutics (NASDAQ:IOVA) is a fledgling pharmaceutical company that specializes…
Stock Ideas
Buy
64
Is AAPL Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 42x
Buy
52
Is NVDA Stock a Buy?
Market Cap: $3.3T
P/E Ratio: 113x
Buy
55
Is MSFT Stock a Buy?
Market Cap: $3.2T
P/E Ratio: 37x
Alerts
Buy
61
QMCO alert for Dec 23
Quantum [QMCO] is up 3.25% over the past day.
Sell
46
NUKK alert for Dec 23
Nukkleus [NUKK] is up 6.6% over the past day.
Sell
1
IIPR alert for Dec 23
Innovative Industrial Properties [IIPR] is down 5.78% over the past day.
